STAT News

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal

By STAT News

1 min read
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights